The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Global Tumor NGS Detection Market Research Report 2024

Global Tumor NGS Detection Market Research Report 2024

Publishing Date : Jul, 2023

License Type :
 

Report Code : 1763466

No of Pages : 115

Ask Your Query

Synopsis
The main purpose of NGS is to discover clinically treatable genetic variants and guide patient treatment.

Global Tumor NGS Detection market is projected to reach US$ 5121.6 million in 2029, increasing from US$ 1835 million in 2022, with the CAGR of 15.8% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Tumor NGS Detection market research.

Key companies engaged in the Tumor NGS Detection industry include Agilent, Thermo Fisher Scientific, BGI Group, Roche Foundation Medicine, Sinopharm Group, Fosunpharma, Novogene, Geneseeq and AmoyDx, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.

When refers to consumption region, % value of Tumor NGS Detection were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Tumor NGS Detection market and estimated to attract more attentions from industry insiders and investors.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Tumor NGS Detection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

By Company

  • Agilent
  • Thermo Fisher Scientific
  • BGI Group
  • Roche Foundation Medicine
  • Sinopharm Group
  • Fosunpharma
  • Novogene
  • Geneseeq
  • AmoyDx
  • Burning Rock Medicine
  • Perkin Elmer
  • Qiagen NV
  • Partek
  • Illumina Inc.
  • Pacific Biosciences of California Inc.
  • Life Technologies Corporation
  • GTH.O
  • Paradigm Diagnostics
  • Oxford Nanopore Technologies Ltd.
  • Eurofins Scientific S.E.

Segment by Type

  • Medical Equipment
  • Consumables

Segment by Application

  • Companion Diagnostics
  • Early Cancer Screening
  • Drug Discovery
  • Other

By Region

  • North America (United States, Canada)
  • Europe (Germany, France, U.K., Italy, Russia, Nordic Countries, Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea,Southeast Asia, India, Australia, Rest of Asia)
  • Latin America (Mexico, Brazil, Rest of Latin America)
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)

The Tumor NGS Detection report covers below items:

Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Global market size, regional market size. Market Opportunities and Challenges
Chapter 3: Companies’ Competition Patterns
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6 to 10: Country Level Value Analysis
Chapter 11: Companies’ Outline
Chapter 12: Market Conclusions
Chapter 13: Research Methodology and Data Source

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Tumor NGS Detection Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Medical Equipment
1.2.3 Consumables
1.3 Market by Application
1.3.1 Global Tumor NGS Detection Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Companion Diagnostics
1.3.3 Early Cancer Screening
1.3.4 Drug Discovery
1.3.5 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Tumor NGS Detection Market Perspective (2018-2029)
2.2 Tumor NGS Detection Growth Trends by Region
2.2.1 Global Tumor NGS Detection Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Tumor NGS Detection Historic Market Size by Region (2018-2023)
2.2.3 Tumor NGS Detection Forecasted Market Size by Region (2024-2029)
2.3 Tumor NGS Detection Market Dynamics
2.3.1 Tumor NGS Detection Industry Trends
2.3.2 Tumor NGS Detection Market Drivers
2.3.3 Tumor NGS Detection Market Challenges
2.3.4 Tumor NGS Detection Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Tumor NGS Detection Players by Revenue
3.1.1 Global Top Tumor NGS Detection Players by Revenue (2018-2023)
3.1.2 Global Tumor NGS Detection Revenue Market Share by Players (2018-2023)
3.2 Global Tumor NGS Detection Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Tumor NGS Detection Revenue
3.4 Global Tumor NGS Detection Market Concentration Ratio
3.4.1 Global Tumor NGS Detection Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Tumor NGS Detection Revenue in 2022
3.5 Tumor NGS Detection Key Players Head office and Area Served
3.6 Key Players Tumor NGS Detection Product Solution and Service
3.7 Date of Enter into Tumor NGS Detection Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Tumor NGS Detection Breakdown Data by Type
4.1 Global Tumor NGS Detection Historic Market Size by Type (2018-2023)
4.2 Global Tumor NGS Detection Forecasted Market Size by Type (2024-2029)
5 Tumor NGS Detection Breakdown Data by Application
5.1 Global Tumor NGS Detection Historic Market Size by Application (2018-2023)
5.2 Global Tumor NGS Detection Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Tumor NGS Detection Market Size (2018-2029)
6.2 North America Tumor NGS Detection Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Tumor NGS Detection Market Size by Country (2018-2023)
6.4 North America Tumor NGS Detection Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Tumor NGS Detection Market Size (2018-2029)
7.2 Europe Tumor NGS Detection Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Tumor NGS Detection Market Size by Country (2018-2023)
7.4 Europe Tumor NGS Detection Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Tumor NGS Detection Market Size (2018-2029)
8.2 Asia-Pacific Tumor NGS Detection Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Tumor NGS Detection Market Size by Region (2018-2023)
8.4 Asia-Pacific Tumor NGS Detection Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Tumor NGS Detection Market Size (2018-2029)
9.2 Latin America Tumor NGS Detection Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Tumor NGS Detection Market Size by Country (2018-2023)
9.4 Latin America Tumor NGS Detection Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Tumor NGS Detection Market Size (2018-2029)
10.2 Middle East & Africa Tumor NGS Detection Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Tumor NGS Detection Market Size by Country (2018-2023)
10.4 Middle East & Africa Tumor NGS Detection Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Agilent
11.1.1 Agilent Company Detail
11.1.2 Agilent Business Overview
11.1.3 Agilent Tumor NGS Detection Introduction
11.1.4 Agilent Revenue in Tumor NGS Detection Business (2018-2023)
11.1.5 Agilent Recent Development
11.2 Thermo Fisher Scientific
11.2.1 Thermo Fisher Scientific Company Detail
11.2.2 Thermo Fisher Scientific Business Overview
11.2.3 Thermo Fisher Scientific Tumor NGS Detection Introduction
11.2.4 Thermo Fisher Scientific Revenue in Tumor NGS Detection Business (2018-2023)
11.2.5 Thermo Fisher Scientific Recent Development
11.3 BGI Group
11.3.1 BGI Group Company Detail
11.3.2 BGI Group Business Overview
11.3.3 BGI Group Tumor NGS Detection Introduction
11.3.4 BGI Group Revenue in Tumor NGS Detection Business (2018-2023)
11.3.5 BGI Group Recent Development
11.4 Roche Foundation Medicine
11.4.1 Roche Foundation Medicine Company Detail
11.4.2 Roche Foundation Medicine Business Overview
11.4.3 Roche Foundation Medicine Tumor NGS Detection Introduction
11.4.4 Roche Foundation Medicine Revenue in Tumor NGS Detection Business (2018-2023)
11.4.5 Roche Foundation Medicine Recent Development
11.5 Sinopharm Group
11.5.1 Sinopharm Group Company Detail
11.5.2 Sinopharm Group Business Overview
11.5.3 Sinopharm Group Tumor NGS Detection Introduction
11.5.4 Sinopharm Group Revenue in Tumor NGS Detection Business (2018-2023)
11.5.5 Sinopharm Group Recent Development
11.6 Fosunpharma
11.6.1 Fosunpharma Company Detail
11.6.2 Fosunpharma Business Overview
11.6.3 Fosunpharma Tumor NGS Detection Introduction
11.6.4 Fosunpharma Revenue in Tumor NGS Detection Business (2018-2023)
11.6.5 Fosunpharma Recent Development
11.7 Novogene
11.7.1 Novogene Company Detail
11.7.2 Novogene Business Overview
11.7.3 Novogene Tumor NGS Detection Introduction
11.7.4 Novogene Revenue in Tumor NGS Detection Business (2018-2023)
11.7.5 Novogene Recent Development
11.8 Geneseeq
11.8.1 Geneseeq Company Detail
11.8.2 Geneseeq Business Overview
11.8.3 Geneseeq Tumor NGS Detection Introduction
11.8.4 Geneseeq Revenue in Tumor NGS Detection Business (2018-2023)
11.8.5 Geneseeq Recent Development
11.9 AmoyDx
11.9.1 AmoyDx Company Detail
11.9.2 AmoyDx Business Overview
11.9.3 AmoyDx Tumor NGS Detection Introduction
11.9.4 AmoyDx Revenue in Tumor NGS Detection Business (2018-2023)
11.9.5 AmoyDx Recent Development
11.10 Burning Rock Medicine
11.10.1 Burning Rock Medicine Company Detail
11.10.2 Burning Rock Medicine Business Overview
11.10.3 Burning Rock Medicine Tumor NGS Detection Introduction
11.10.4 Burning Rock Medicine Revenue in Tumor NGS Detection Business (2018-2023)
11.10.5 Burning Rock Medicine Recent Development
11.11 Perkin Elmer
11.11.1 Perkin Elmer Company Detail
11.11.2 Perkin Elmer Business Overview
11.11.3 Perkin Elmer Tumor NGS Detection Introduction
11.11.4 Perkin Elmer Revenue in Tumor NGS Detection Business (2018-2023)
11.11.5 Perkin Elmer Recent Development
11.12 Qiagen NV
11.12.1 Qiagen NV Company Detail
11.12.2 Qiagen NV Business Overview
11.12.3 Qiagen NV Tumor NGS Detection Introduction
11.12.4 Qiagen NV Revenue in Tumor NGS Detection Business (2018-2023)
11.12.5 Qiagen NV Recent Development
11.13 Partek
11.13.1 Partek Company Detail
11.13.2 Partek Business Overview
11.13.3 Partek Tumor NGS Detection Introduction
11.13.4 Partek Revenue in Tumor NGS Detection Business (2018-2023)
11.13.5 Partek Recent Development
11.14 Illumina Inc.
11.14.1 Illumina Inc. Company Detail
11.14.2 Illumina Inc. Business Overview
11.14.3 Illumina Inc. Tumor NGS Detection Introduction
11.14.4 Illumina Inc. Revenue in Tumor NGS Detection Business (2018-2023)
11.14.5 Illumina Inc. Recent Development
11.15 Pacific Biosciences of California Inc.
11.15.1 Pacific Biosciences of California Inc. Company Detail
11.15.2 Pacific Biosciences of California Inc. Business Overview
11.15.3 Pacific Biosciences of California Inc. Tumor NGS Detection Introduction
11.15.4 Pacific Biosciences of California Inc. Revenue in Tumor NGS Detection Business (2018-2023)
11.15.5 Pacific Biosciences of California Inc. Recent Development
11.16 Life Technologies Corporation
11.16.1 Life Technologies Corporation Company Detail
11.16.2 Life Technologies Corporation Business Overview
11.16.3 Life Technologies Corporation Tumor NGS Detection Introduction
11.16.4 Life Technologies Corporation Revenue in Tumor NGS Detection Business (2018-2023)
11.16.5 Life Technologies Corporation Recent Development
11.17 GTH.O
11.17.1 GTH.O Company Detail
11.17.2 GTH.O Business Overview
11.17.3 GTH.O Tumor NGS Detection Introduction
11.17.4 GTH.O Revenue in Tumor NGS Detection Business (2018-2023)
11.17.5 GTH.O Recent Development
11.18 Paradigm Diagnostics
11.18.1 Paradigm Diagnostics Company Detail
11.18.2 Paradigm Diagnostics Business Overview
11.18.3 Paradigm Diagnostics Tumor NGS Detection Introduction
11.18.4 Paradigm Diagnostics Revenue in Tumor NGS Detection Business (2018-2023)
11.18.5 Paradigm Diagnostics Recent Development
11.19 Oxford Nanopore Technologies Ltd.
11.19.1 Oxford Nanopore Technologies Ltd. Company Detail
11.19.2 Oxford Nanopore Technologies Ltd. Business Overview
11.19.3 Oxford Nanopore Technologies Ltd. Tumor NGS Detection Introduction
11.19.4 Oxford Nanopore Technologies Ltd. Revenue in Tumor NGS Detection Business (2018-2023)
11.19.5 Oxford Nanopore Technologies Ltd. Recent Development
11.20 Eurofins Scientific S.E.
11.20.1 Eurofins Scientific S.E. Company Detail
11.20.2 Eurofins Scientific S.E. Business Overview
11.20.3 Eurofins Scientific S.E. Tumor NGS Detection Introduction
11.20.4 Eurofins Scientific S.E. Revenue in Tumor NGS Detection Business (2018-2023)
11.20.5 Eurofins Scientific S.E. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock